论文部分内容阅读
单克隆抗体技术给确立和定量肿瘤标记方法的改善以新的希望。在这些制质中,癌相关的碳水化物抗原CA19—9和CA50对临床应用最有希望。本文分析靠血透维持的尿毒症患者(其中有些患癌)的血清CA19—9和CA50浓度并与相应的CEA测定比较,目的在确定肾功能衰竭对这些试验的解释有何影响。作者研究了2组用血液透析维持的尿毒症患者,组1∶64名患者(男36,女28,年龄21～70岁,平均42.7岁),均无癌或其他非癌而可能影响结果的情况。患者的肾脏病是慢性肾小球肾炎24
Monoclonal antibody technology gives new hope to the establishment and quantification of improved methods of tumor labeling. Among these qualities, the cancer-associated carbohydrate antigens CA19-9 and CA50 are most promising for clinical use. This article examines serum CA19-9 and CA50 levels in uremic patients, some of whom have cancer, maintained by hemodialysis and compares them with the corresponding CEA test in order to determine how renal failure affects interpretation of these tests. The authors studied two groups of uremic patients who were maintained on hemodialysis. Patients in the 1:64 group (36 males, 28 females, 21-70 years of age, mean 42.7 years) had no cancer or other non-cancerous effects that could affect outcomes Happening. The patient’s kidney disease is chronic glomerulonephritis24